FDA clears Lensar’s adaptive cataract treatment system
Click Here to Manage Email Alerts
Lensar received FDA 510(k) clearance for its next-generation Ally adaptive cataract treatment system, according to a press release.
Ally is the first FDA-cleared platform that allows cataract surgeons to complete femtosecond-laser-assisted cataract surgery (FLACS) in a single environment, the release said. The system uses adaptive intelligence to optimize fragmentation patterns and energy settings as well as to automatically determine cataract density.
“Our mission has been to develop a platform where surgeons can seamlessly perform the entire FLACS procedure in a single setting, improve workflow efficiencies, and most importantly, help surgeons deliver better outcomes through the advanced technologies in the Ally system,” Nick Curtis, CEO of Lensar, said in the release.
Lensar plans to deliver the first Ally systems in the third quarter through a targeted initial launch followed by wide availability in 2023.
Read more about
Click Here to Manage Email Alerts